Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Coplanar and non-coplanar VMAT facilitate OAR dose sparing in central lung SBRT

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Vis graf over relationer

BACKGROUND: We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients' outcomes.

METHODS: Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005-2014) were analyzed. The patients' GTV and CTV were defined based on MR (n = 521) or FET-PET/MR (n = 190), and were treated using conformal radiotherapy (CRT, n = 159) or image-guided volumetric modulated arc therapy with hippocampal sparing (IG-VMAT, n = 362). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between clinical data, dosimetry data, treatment technology, for PFS and overall survival (OS) were explored.

RESULTS: The PFS (7 months) and OS (15 months) were unaffected by CRT, IG-VMAT and FET-PET technology. Mean brain dose was correlated with tumor volume, and was lower for IG-VMAT vs. CRT (p < 0.001). Larger mean brain dose was associated with inferior PFS (univariate/multivariate Cox models, p < 0.001) and OS (univariate, p < 0.001). Multivariate Cox models revealed association of larger mean brainstem dose (p < 0.001), BTV (p = 0.045), steroid use at baseline (p = 0.003), age (p = 0.019) and MGMT status (p = 0.022) with lower OS.

CONCLUSIONS: Introduction of hippocampal-sparing IG-VMAT technology appeared to be safe, and may have reduced toxicity and cognitive impairment. Larger mean brain dose was strongly associated with inferior PFS and OS.

OriginalsprogEngelsk
TidsskriftRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind130
Sider (fra-til)149-155
ISSN0167-8140
DOI
StatusUdgivet - 2019

ID: 56319972